Skip to main content
SpringerLink
Log in

Overview of US Prostate Cancer Trends in the Era of PSA Screening

  • Chapter
Prostate Cancer Screening

Part of the book series: Current Clinical Urology ((CCU))

Summary

Prostate cancer rates in the United States have changed radically over the last two decades. The introduction of prostate-specific antigen (PSA) screening impacted incidence substantially; however, in the absence of randomized clinical trials, its role in the precipitous mortality decline remains unclear. Simultaneous advances in treatment, shifting patterns of care, and changing health behaviors may also have contributed to this decline. Two veins of investigation–-ecologic and modeling studies–-provide insights into the benefits and costs of PSA screening, with the latter positioned to help design optimal intervention policies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\(^{\ast}\)Stat Database: Incidence–-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973–2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.

  2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\(^{\ast}\)Stat Database: Mortality–-All COD, Public-Use With State, Total U.S. (1969–2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

  3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Prevalence database: “US Estimated Complete Prevalence Counts on 1/1/2005”. National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2008, based on the November 2007 SEER data submission.

  4. Mariotto, A., Etzioni, R., Krapcho, M., and Feuer, E. J. (2007) Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey Cancer 109, 1877–86.

    Article  PubMed  Google Scholar 

  5. Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., and Carroll, P. R. (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95, 981–9.

    Article  PubMed  Google Scholar 

  6. Zeliadt, S., Potosky, A., Etzioni, R., Ramsey, S., and Penson, D. (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999 Urology 64, 1171–6.

    Article  PubMed  Google Scholar 

  7. Etzioni, R., Gulati, R., Falcon, S., and Penson, D. (2008) Impact of PSA screening on the incidence of advanced stage prostate cancer in the US: A surveillance modeling approach Med Decis Making 28(3), 323–31.

    Article  PubMed  Google Scholar 

  8. Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D., Sanders, M. M., and Fine, J. (2005) Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97, 1248–53.

    Article  PubMed  Google Scholar 

  9. Thompson, I. M., Canby-Hagino, E., and Lucia, M. S. (2005) Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor J Natl Cancer Inst 97, 1236–7.

    Article  PubMed  Google Scholar 

  10. Feuer, E. J., and Wun, L. M. (1992) How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach Am J Epidemiol 136, 1423–36.

    CAS  PubMed  Google Scholar 

  11. Etzioni, R., Penson, D. F., Legler, J. M., Di Tommaso, D., Boer, R., Gann, P. H., and Feuer, E. J. (2002) Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94, 981–90.

    PubMed  Google Scholar 

  12. Tsodikov, A., Szabo, A., and Wegelin, J. (2006) A population model of prostate cancer incidence Stat Med 25, 2846–66.

    Article  CAS  PubMed  Google Scholar 

  13. Telesca, D., Etzioni, R., and Gulati, R. (2008) Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends Biometrics 64, 10–9.

    Article  PubMed  Google Scholar 

  14. Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., and De Koning, H. J. (2008, Submitted for publication) Reconciling Differing Estimates of Lead Time and Overdiagnosis Due to PSA Screening: Results from the Cancer Intervention and Surveillance Modeling Network J Natl Cancer Inst.

    Google Scholar 

  15. Draisma, G., Boer, R., Otto, S. J., Van Der Cruijsen, I. W., Damhuis, R. A., Schröder, F. H., and De Koning, H. J. (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95, 868–78.

    Article  PubMed  Google Scholar 

  16. Weiss, N. S., and Rossing, M. A. (1996) Healthy screened bias in epidemiologic studies of cancer incidence Epidemiology 7, 319–22.

    CAS  PubMed  Google Scholar 

  17. Lu-Yao, G., Albertsen, P. C., Stanford, J. L., Stukel, T. A., Walker-Corkery, E. S., and Barry, M. J. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325, 740.

    Article  PubMed  Google Scholar 

  18. Shaw, P. A., Etzioni, R., Zeliadt, S. B., Mariotto, A., Karnofski, K., Penson, D. F., Weiss, N. S., and Feuer, E. J. (2004) An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States Am J Epidemiol 160, 1059–69.

    Article  PubMed  Google Scholar 

  19. Zeliadt, S. B., Potosky, A. L., Etzioni, R., Ramsey, S. D., and Penson, D. F. (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999 Urology 64, 1171–6.

    Article  PubMed  Google Scholar 

  20. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Mattelaer, J., Lopez Torecilla, J., Pfeffer, J. R., Lino Cutajar, C., Zurlo, A., and Pierart, M. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360, 103–6.

    Article  CAS  PubMed  Google Scholar 

  21. Albertsen, P. C. (2003) The prostate cancer conundrum J Natl Cancer Inst 95, 930–1.

    Article  PubMed  Google Scholar 

  22. Etzioni, R., Legler, J. M., Feuer, E. J., Merrill, R. M., Cronin, K. A., and Hankey, B. F. (1999) Cancer surveillance series: Interpreting trends in prostate cancer–-Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality J Natl Cancer Inst 91, 1033–9.

    Article  CAS  PubMed  Google Scholar 

  23. Etzioni, R., Tsodikov, A., Mariotto, A., Szabo, A., Falcon, S., Wegelin, J., Ditommaso, D., Karnofski, K., Gulati, R., Penson, D. F., and Feuer, E. (2008) Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19, 175–81.

    Article  PubMed  Google Scholar 

  24. Feuer, E. J., Mariotto, A., and Merrill, R. (2002) Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates Cancer 95, 870–80.

    Article  PubMed  Google Scholar 

  25. Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S., and Carroll, P. R. (2004) The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J Clin Oncol 22, 2141–9.

    Article  PubMed  Google Scholar 

  26. Kristal, A. R., and Gong, Z. (2007) Obesity and prostate cancer mortality Future Oncol 3, 557–67.

    Article  PubMed  Google Scholar 

  27. Gong, Z., Agalliu, I., Lin, D. W., Stanford, J. L., and Kristal, A. R. (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men Cancer 109, 1192–202.

    Article  PubMed  Google Scholar 

  28. Gong, Z., Neuhouser, M. L., Goodman, P. J., Albanes, D., Chi, C., Hsing, A. W., Lippman, S. M., Platz, E. A., Pollak, M. N., Thompson, I. M., and Kristal, A. R. (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 15, 1977–83.

    Article  PubMed  Google Scholar 

  29. Etzioni, R., and Feuer, E. (In Press) Learning from international studies of prostate cancer mortality: A cautionary tale Lancet Oncol .

    Google Scholar 

  30. Kim, H. J., Fay, M. P., Feuer, E. J., and Midthune, D. N. (2000) Permutation tests for joinpoint regression with applications to cancer rates Stat Med 19, 335–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Ruth Etzioni MD

  2. Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

    Roman Gulati MS

  3. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA

    Angela Mariotto PHD

Authors
  1. Ruth Etzioni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roman Gulati MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Mariotto PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Mathematics, Technical University, Garching, Germany

    Donna P. Ankerst Ph.D. (Professor) (Professor)

  2. Associate Professor, Departments of Urology, and Epidemiology/Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Donna P. Ankerst Ph.D. (Professor) (Professor)

  3. Member, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, UK

    Catherine M. Tangen DrPh

  4. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Ian M. Thompson Jr MD (Professor and Chair) (Professor and Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Etzioni, R., Gulati, R., Mariotto, A. (2009). Overview of US Prostate Cancer Trends in the Era of PSA Screening. In: Ankerst, D.P., Tangen, C.M., Thompson, I.M. (eds) Prostate Cancer Screening. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-281-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-281-0_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-280-3

  • Online ISBN: 978-1-60327-281-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation